Skip to main content

Multiple Sclerosis 3

In Order to Read Online or Download Multiple Sclerosis 3 Full eBooks in PDF, EPUB, Tuebl and Mobi you need to create a Free account. Get any books you like and read everywhere you want. Fast Download Speed ~ Commercial & Ad Free. We cannot guarantee that every book is in the library!

Multiple Sclerosis

Multiple Sclerosis Book
Author : Neil Scolding,Alastair Wilkins
Publisher : Oxford University Press, USA
Release : 2012-07-05
ISBN : 0199603251
Language : En, Es, Fr & De

GET BOOK

Book Description :

Part of the Oxford Neurology Library series, this practical pocketbook will summarise the latest understanding of what might cause the disease, the methods of diagnosis and assessment, and current management techniques.

Multiple Sclerosis 3

Multiple Sclerosis 3 Book
Author : Anonim
Publisher : Unknown
Release : 2006
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Multiple Sclerosis 3 book written by , available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Multiple Sclerosis

Multiple Sclerosis Book
Author : J. F. Hallpike,Colin Wallace Maitland Adams,Wallace W. Tourtellotte
Publisher : Unknown
Release : 1983
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Multiple Sclerosis book written by J. F. Hallpike,Colin Wallace Maitland Adams,Wallace W. Tourtellotte, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Multiple Sclerosis 3 Volume 34 E Book

Multiple Sclerosis 3  Volume 34 E Book Book
Author : Claudia Lucchinetti,Reinhard Hohlfeld
Publisher : Elsevier Health Sciences
Release : 2009-10-29
ISBN : 1437711294
Language : En, Es, Fr & De

GET BOOK

Book Description :

Multiple Sclerosis 3 emphasizes the latest in the pharmacologic treatment of this incurable inflammatory demyelinating disorder. Primary editors Claudia Lucchinetti, MD, and Reinhard Hohlfeld, MD, with the aid of all new contributors, present a complete and current reference on multiple sclerosis that includes discussions of such hot topics as Biomarkers, Genomics, and Surrogate Outcomes in MS; Pediatric MS; Transverse Myelitis; Attack Therapies in MS; Current Disease-Modifying Therapeutic Strategies in MS; Management of Aggressive MS; Symptomatic Therapies in MS; Complementary and Alternative Medical Therapies; and Strategies to Promote Neuroprotection and Repair. Distinguish between MS and other similar demyelinating disorders and know the best and most aggressive methods of treatment. This title in the Blue Books of Neurology series is exactly what you need to treat the disease and its relapses. Covers the latest clinical advances and relevant discussions—Biomarkers, Genomics, and Surrogate Outcomes in MS; Pediatric MS; Transverse Myelitis; Attack Therapies in MS; Current Disease-Modifying Therapeutic Strategies in MS; Management of Aggressive MS; Symptomatic Therapies in MS; Complementary and Alternative Medical Therapies; and Strategies to Promote Neuroprotection and Repair—to bring you up to date and keep your practice state-of-the-art. Features a greater emphasis on practical management to help you determine the type of multiple sclerosis and the best course of therapy. Focuses on pharmaceutical therapies so you know the best and most aggressive methods and which drugs to use for treatment. Includes extensive information on differential diagnosis so that you can clearly distinguish between multiple sclerosis and other similar demyelinating disorders. Presents expert new editors and experienced contributing authors for the most current and relevant practice information. Emphasizes the pharmacologic management of patients with multiple sclerosis to address treating the actual disease and its relapses as well as treating the symptoms.

Biomarkers in Multiple Sclerosis

Biomarkers in Multiple Sclerosis Book
Author : U. Utz
Publisher : IOS Press
Release : 2006-11
ISBN : 9781586036973
Language : En, Es, Fr & De

GET BOOK

Book Description :

"Several processes are presumed to sequentially or simultaneously contribute to the pathophysiology of multiple sclerosis (MS). Biomarkers indicative of these processes would hold great potential for (1) MS diagnostics and identification of disease stages and subcategories; (2) prediction of onset and disease course; (3) treatment selection and improved prognosis of treatment success; and (4) the evaluation of novel therapeutics. Though it is unlikely that any one marker could function as a true surrogate or stand alone, biomarker combinations or patterns could provide insight into the mechanism of action of a drug and could suffice for the pre-screening of prospective therapeutics. This publication examines the potential of biomarkers in the context of MS. It explores the current state of biomarker research for MS, barriers to progress and possible solutions and priorities. Many biomarkers are covered that are relevant to disease processes such as inflammation, axonal damage, demyelination, oxidative stress and remyelination. Individual biomarkers and biomarker approaches are discussed on their usefulness for the advancement of categories 1 to 4 listed above."

Multiple Sclerosis

Multiple Sclerosis Book
Author : Johnson Mbabazi Frsph
Publisher : Unknown
Release : 2019-10-02
ISBN : 9781697115239
Language : En, Es, Fr & De

GET BOOK

Book Description :

The society also estimates that 2.3 million people live with MS globally. It is most commonly diagnosed in people in their 20s and 30s, although it can develop at any age. It's about 2 to 3 times more common in women than men. Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that involves demyelination and axonal degeneration. Even though considerable progress has been made in clinical drug development for relapsing remitting MS, treatment of the progressive forms of the disease, which are characterised clinically by the build-up of disability in the absence of relapses, remains unsatisfactory. This unmet clinical necessity is related to the difficulty of the pathophysiological mechanisms involved in MS progression. Chronic inflammation, which arises behind a closed blood brain barrier with activation of microglia and continued involvement of T cells and B cells, is a distinctive pathophysiological feature. Inflammation can enhance mitochondrial damage in neurons, which, consequently, develop an energy deficit, further reducing axonal health. The growth-inhibitory and inflammatory environment of lesions also impairs remyelination, a repair process that might protect axons from degeneration. Furthermore, neurodegeneration is enhanced by the altered expression of ion channels on denuded axons. Although there is no current cure of MS, some current drugs appear to reduce some frequent relapses and delay disease progression to some extent. This humanised immunoglobulin antibody medication is the only Dimethyltryptamine (DMT) approved by the FDA to treat both the relapse-remitting and primary-progressive forms of MS . Clinical trials showed it reduced relapse rate in relapsing disease and slowed worsening of disability in both forms of the disease. Currently, therapeutic options for multiple sclerosis increased, several clinical dilemmas arose, and clinicians had to start making decisions about which therapy to use, when to treat patients, and when and how to switch medications in patients with a suboptimal response. These clinical dilemmas continue today, but treatment strategies continue to be refined. Although FDA(Food and Drug Administration,2019) -approved drugs to treat relapsing forms of MS in adults include dimethyl fumarate and teriflunomide, both taken orally.

Handbook of Multiple Sclerosis

Handbook of Multiple Sclerosis Book
Author : Stuart D. Cook
Publisher : CRC Press
Release : 2001-03-30
ISBN : 0824741846
Language : En, Es, Fr & De

GET BOOK

Book Description :

Reporting on the latest advances made in treating multiple sclerosis (MS) and continuing the high standards set by earlier editions, the Handbook of Multiple Sclerosis, Third Edition examines a wide range of topics from etiology to treatment options. Analyzes recent developments in the natural history, immunopathology, lesion evolution, and

McAlpine s Multiple Sclerosis

McAlpine s Multiple Sclerosis Book
Author : Douglas McAlpine,Alastair Compston
Publisher : Elsevier Health Sciences
Release : 2005
ISBN : 044307271X
Language : En, Es, Fr & De

GET BOOK

Book Description :

Comprehensive text highlighting current clinical research in the area of multiple sclerosis. Includes expanded coverage of genetics, neurobiology, pathophysiology, and historical background.

Primary Progressive Multiple Sclerosis

Primary Progressive Multiple Sclerosis Book
Author : M. Filippi,G. Comi
Publisher : Springer Science & Business Media
Release : 2012-12-06
ISBN : 8847022347
Language : En, Es, Fr & De

GET BOOK

Book Description :

"Why are there no effective treatments for my condition? Why do researchers exclude patients with primary progressive multiple sclerosis from enrolling in clinical trials? Please let me know if you hear of studies that I might be allowed to enter or treatments that I could try for my condition. " Thus, in recent years, the sad lament of the patient with primary progressive MS (PPMS). This variant, often in the guise of a chronic progressive myelopathy or, less commonly, progressive cerebellar or bulbar dysfunction, usually responds poorly to corticosteroids and rarely seems to benefit to a significant degree from intensive immunosuppressive treatments. In recent years, most randomized clin ical trials have excluded PPMS patients on two counts. Clinical worsening devel ops slowly in PPMS and may not be recognized during the course of a 2-or 3-year trial even in untreated control patients. This factor alone adds to the potential for a type 2 error or, at the very least, inflates the sample size and duration of the trial. In addition, there is mounting evidence that progressive axonal degeneration and neuronal loss (rather than active, recurrent inflammation) may be important components of the pathology in this form of the disease. Although contemporary trials are evaluating whether PPMS patients may benefit from treatment with the ~-interferons and glatiramer acetate, preliminary, uncontrolled clinical experi ence suggests that the results may not be dramatic.

Overcoming Multiple Sclerosis

Overcoming Multiple Sclerosis Book
Author : George Jelinek
Publisher : Allen & Unwin
Release : 2016-07-01
ISBN : 1760112550
Language : En, Es, Fr & De

GET BOOK

Book Description :

Overcoming Multiple Sclerosis is an established and successful program of treatment. Once a diagnosis of MS meant inevitable decline and disability. Now thousands of people around the world are living healthy, active lives on the Overcoming Multiple Sclerosis recovery program. Overcoming Multiple Sclerosis explains the nature of MS and outlines an evidence-based 7 step program for recovery. Professor George Jelinek devised the program from an exhaustive analysis of medical research when he was first diagnosed with MS in 1999. It has been refined through major ongoing international clinical studies under Professor Jelinek's leadership, examining the lifestyles of several thousand people with MS world-wide and their health outcomes. Overcoming Multiple Sclerosis is invaluable for anyone recently diagnosed with MS, living with MS for years, or with a family member with MS. It makes an ideal resource for doctors treating people with MS. 'I would have no hesitation in recommending Overcoming Multiple Sclerosis to my patients, but also to my friends and colleagues.' Professor Gavin Giovannoni, MBBCh, PhD, FCP (S.A., Neurol.), FRCP, FRCPath, Chair of Neurology, Blizard Institute, Barts and The London School of Medicine and Dentistry 'Overcoming Multiple Sclerosis combines hard scientific evidence with practical advice and compassion. It will be of benefit to nearly everybody affected by MS and I heartily recommend it.' Dr Peter Fisher FRCP , Physician to Her Majesty Queen Elizabeth II, and Director of Research, Royal London Hospital for Integrated Medicine

Experimental Models of Multiple Sclerosis

Experimental Models of Multiple Sclerosis Book
Author : Ehud Lavi,Cris S. Constantinescu
Publisher : Springer Science & Business Media
Release : 2008-01-03
ISBN : 0387255184
Language : En, Es, Fr & De

GET BOOK

Book Description :

Multiple Sclerosis (MS) is an enigmatic immune mediated disease of the central nervous system that affects about 350,000 individuals in the US, and many more around the world. The mechanism of this disease is largely unknown and there is no cure for it. However, there are several well-characterized experimental animal models that help us understand and speculate about potential mechanisms of pathology in this disease. Many of the experimental therapies designed for this disease rely on testing the drugs in animal models before using it in clinical trials. This book combines for the first time the different experimental models for MS (including immune-mediated and viral) under one roof, and highlights aspects that are different or shared among these experimental models. It’s aim is to improve our understanding of this devastating disease and help us think about potential additional therapies for it.

Multiple Sclerosis

Multiple Sclerosis Book
Author : Lorraine De Souza,Action and Research for Multiple Sclerosis
Publisher : Springer
Release : 2013-12-14
ISBN : 1489931074
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Multiple Sclerosis book written by Lorraine De Souza,Action and Research for Multiple Sclerosis, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Emerging Drugs and Targets for Multiple Sclerosis

Emerging Drugs and Targets for Multiple Sclerosis Book
Author : Ana Martinez
Publisher : Royal Society of Chemistry
Release : 2019-06-18
ISBN : 1788018060
Language : En, Es, Fr & De

GET BOOK

Book Description :

Multiple sclerosis (MS) is a complex disease with a presumed autoimmune aetiology and few current effective treatments. Disease modifying therapies focus on the altering the natural course of relapsing and remitting MS, targeting the inflammatory response. Other targets involve tacking the cause of the disease – demyelination of axons through remyelination therapies. Due to several recent breakthroughs in the understanding of the pathophysiology of MS new targets for remyelination and immunomodulation are rapidly emerging. This book provides a comprehensive overview of drug discovery and development for the molecular basis of the disease, from new targets to drugs currently in clinical development, cellular and animal disease models to biomarkers for diagnosis and assessment in clinical trials. Emerging Drugs and Targets for Multiple Sclerosis is an ideal reference for any student or researcher interested in drug development for neurodegenerative diseases, autoimmune diseases and MS in particular.

Primer on Multiple Sclerosis

Primer on Multiple Sclerosis Book
Author : Barbara S. Giesser
Publisher : Oxford University Press
Release : 2016-02-11
ISBN : 019934101X
Language : En, Es, Fr & De

GET BOOK

Book Description :

Primer on Multiple Sclerosis, 2nd Edition is an updated reference manual for the practicing clinician. It covers the range of information needed to treat persons with MS, beginning with basic science and immunopathology, thorough differential diagnosis, symptom management and disease modifying therapies. This essential book also includes material covering new and experimental strategies as well as a review of commonly used complementary and alternative modalities that are used by persons with MS.Multiple Sclerosis (MS) is the most common demyelinating disease of the CNS and the third most common cause of disability among young adults. The complex management issues that are often present in the care of individuals with MS may demand the participation of health care professionals from a variety of disciplines, although the team is usually led by a neurologist. It is therefore essential for the neurologist to have a thorough grounding in the basic science and clinical phenomenology of MS. In this second edition of Primer on Multiple Sclerosis, the latest updates on therapeutics are provided, including new medications that have been FDA- approved since the first edition. Includes new diagnostic criteria, as well as any advances made in current diagnostic techniques, e.g. new imaging metrics. Important new information in the basic sciences and pathophysiology of MS is provided as well as newer epidemiologic studies. Treatment algorithms for common symptoms will be expanded, as well as any new guidelines for switching medications for Disease Modifying treatment "failures". The chapter on alternative and complimentary therapies discusses new research on CCSVI. The chapter on legal issues includes information on the putative effect of the Affordable Health Care Act on access to neurologic care and treatments. Finally, there is expanded discussion of progressive forms of MS both from a basic science and treatment perspective.

McAlpine s Multiple Sclerosis

McAlpine s Multiple Sclerosis Book
Author : Douglas McAlpine
Publisher : Unknown
Release : 1985
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download McAlpine s Multiple Sclerosis book written by Douglas McAlpine, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Biomarkers and Disease Activity in Multiple Sclerosis

Biomarkers and Disease Activity in Multiple Sclerosis Book
Author : Irene Håkansson
Publisher : Linköping University Electronic Press
Release : 2019-10-07
ISBN : 9176850129
Language : En, Es, Fr & De

GET BOOK

Book Description :

This thesis focuses on disease activity in clinically isolated syndrome (CIS) and newly diagnosed relapsing remitting multiple sclerosis (RRMS). The papers are based on data from 41 patients in a prospective longitudinal cohort study. All patients were untreated at baseline. Age- and sex-matched healthy controls (n=22) for blood and cerebrospinal fluid (CSF) samples were recruited from blood donors. Paper I evaluated the prognostic value of baseline levels of CXCL1, CXCL8, CXCL10, CXCL13, CCL22, neurofilament light chain (NFL), neurofilament heavy chain, glial fibrillary acidic protein, chitinase-3-like-1 (CHI3L1), matrix metalloproteinase-9 (MMP-9) and osteopontin in CSF in relation to disease activity during the first two years of follow-up. Disease activity was defined as clinical relapses, new T2 lesions in brain magnetic resonance imaging (MRI) and/or sustained Expanded Disability Status Scale (EDSS) progression. Absence of these three signs of disease activity was called no evidence of disease activity (NEDA-3). Logistic regression analysis showed that NFL in CSF was the best predictive marker of disease activity and correctly classified 93% of the patients with evidence of disease activity during two years of follow-up and 67% of those without. Paper II presented four year follow-up data from the cohort and also included brain volume data as well as serum levels of NFL. The correlation between NFL in CSF and serum was fairly strong (r=0.74, p<0.001). NFL in CSF was associated with new T2 lesions as well as with brain volume loss, whereas CHI3L1 in CSF was associated mainly with brain volume loss and CXCL1, CXCL10, CXCL13, CCL22 and MMP-9 in CSF were mainly associated with new T2 lesions. Taken together, paper I and II confirm and extend the knowledge of NFL as a useful biomarker in CIS and RRMS and suggests that NFL, rather than total brain volume loss, could be included in an expanded NEDA concept and used in clinical monitoring of disease activity/treatment effect. Although serum levels of NFL were correlated with the corresponding CSF levels, CSF-NFL showed a stronger association to subsequent disease activity (NEDA-3). Paper III addressed the patients´ self-reported Modified Fatigue Impact Scale (MFIS) scores in relation to other cohort study data. MFIS scores correlated with other self-assessment questionnaire data (Hospital Anxiety and Depression scale (HAD), Multiple Sclerosis Impact Scale 29 (MSIS-29) and Short Form 36 (SF-36) scores (Spearman´s rho 0.45-0.78, all p?0.01)) but not with EDSS ratings, number of T2 lesions, total brain volume or NFL levels, indicating that subjective fatigue scores are not well reflected by some commonly used and objectively measurable disease parameters. Paper IV focused on the complement factors C1q, C3, C3a and sC5b-9 in CSF and plasma. CSFC1q was significantly higher in patients than in controls at baseline. The subgroup of patients with ongoing relapse at baseline also had higher levels of CSF-C3a than controls. Baseline levels of CSF-C1q and CSF-C3a correlated significantly with several pro-inflammatory chemokines as well as with MMP-9, CHI3L1 and NFL in CSF. Baseline CSF-C3a also correlated significantly with the number of T2 lesions and Gadolinium enhancing lesions in brain MRI at baseline, as well as with the number of new T2 lesions during follow-up. This study indicates that the complement system is involved already at early stages of MS. It also suggests that especially CSF-C1q and CSF-C3a levels are associated with other neuroinflammatory and neurodegenerative markers and that CSF-C3a levels may carry some prognostic information.

Overcoming Multiple Sclerosis

Overcoming Multiple Sclerosis Book
Author : George Jelinek
Publisher : ReadHowYouWant.com
Release : 2010-10-19
ISBN : 1459603877
Language : En, Es, Fr & De

GET BOOK

Book Description :

Large Print.

Multiple Sclerosis and Related Disorders

Multiple Sclerosis and Related Disorders Book
Author : Francois Bethoux, MD,Robert J. Fox, MD
Publisher : Demos Medical Publishing
Release : 2013-06-18
ISBN : 1617051276
Language : En, Es, Fr & De

GET BOOK

Book Description :

Multiple Sclerosis and Related Disorders provides evidence-based data and experience-based guidance for delivering quality long-term care to MS patients. Information on disease history, pathophysiology, and biology is included to provide clinicians with a framework for understanding current diagnosis, monitoring, and treatment strategies for these disorders. In addition to thoroughly reviewing the newest disease-modifying treatments, the authors have devoted significant focus to the symptoms that frequently manifest and their treatment options. Symptoms and functional limitations are the ìface of the diseaseî for patients, and present their own set of challenges for practitioners. The book proceeds through diagnosis (initial symptoms, criteria and classification, imaging, lab tests, and differential diagnosis), approved treatments for the various MS types including emerging therapies where appropriate, symptom management, rehabilitative issues, general health and wellness, and an overview of MS clinical trials. Special populations, societal and family issues, and related disorders that are often mistaken for MS are also covered. Dedicated chapters on neuromyelitis optica and acute disseminated encephalomyelitis incorporate newer diagnostic criteria. Because comorbidities often make the management of MS-related disability more complex, the book addresses these comorbidities as part of a comprehensive management plan. To enhance the clinical utility, critical-to-know information and management pearls are boxed for quick reference and most chapters include lists of ìKey Pointsî for clinicians, and for patients and families. Illustrations, tables, graphs, assessment scales, and up-to-date MRI imaging inform the text throughout. The treatment chapters include specific recommendations where available and highlight areas of controversy. Illustrative cases go beyond the literature to amplify clinical recommendations and provide real-world guidance for practitioners. Illustrations, tables, graphs, assessment scales, and up-to-date MRI imaging inform the text throughout. Multiple Sclerosis and Related Disorders features: Comprehensive clinical reference for all members of the MS care team Focus on practical approaches to diagnosis, treatment, counseling, and rehabilitative strategies Reviews the latest disease modifying therapies Extensive chapters on symptom management and womenís issues in MS Edited and written primarily by expert clinicians at Cleveland Clinic/Mellen Center Evidence- and experience-based guidance Dedicated chapters on neuromyelitis optica and acute disseminated encephalomyelitis incorporating newer diagnostic criteria Includes treatment guidelines and numerous illustrations, tables, scales; key information is highlighted for quick reference